Skip to content

Study · Observational study · n = 44,470 · 2026

3 results

Tirzepatide versus semaglutide for the prevention of mild cognitive impairment, dementia, and Alzheimer's disease in type 2 diabetes: A real-world, retrospective cohort study.

da Silva AMP, Januário Campos Cardoso L, Batista S, Gonçalves OR, Paranhos T, Teixeira IPS, Guimarães PD, Espinosa Franco B, Cal H, Salles JEN, Perry G, Høilund-Carlsen PF, Santos DH

Journal of diabetes and its complications25 Feb 2026Cited by 1 (Europe PMC)

PMID41825212 (opens in a new tab)DOI10.1016/j.jdiacomp.2026.109306 (opens in a new tab)PepBankPUB-41825212
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, starting tirzepatide was associated with a lower risk of mild cognitive impairment than starting semaglutide (RR 0.12).

    In plain wordsIn adults with type 2 diabetes, starting tirzepatide was linked to less mild memory decline than starting semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseIncident mild cognitive impairment
    Study

    n = 44,470

    Comparator
    Semaglutide
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    RR
    0.12 ratio
    MCI, tirzepatide vs semaglutide

    Source sentences

    Summary
    Compared with semaglutide, initiation of tirzepatide was associated with a lower risk of MCI (RR 0.12; 95% CI 0.06-0.22)
    2 context sentences
    Summary · context
    Adults with T2DM who initiated tirzepatide or semaglutide were included.
    Summary · context
    Propensity score matching (1:1) was applied to balance baseline characteristics, including age, sex, race, and cardiometabolic and psychiatric comorbidities.
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, starting tirzepatide was associated with a lower risk of dementia than starting semaglutide (RR 0.15).

    In plain wordsIn adults with type 2 diabetes, starting tirzepatide was linked to less dementia than starting semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseIncident dementia
    Study

    n = 44,470

    Comparator
    Semaglutide
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    RR
    0.15 ratio
    dementia, tirzepatide vs semaglutide

    Source sentences

    Summary
    dementia (RR 0.15; 95% CI 0.09-0.26)
    2 context sentences
    Summary · context
    Adults with T2DM who initiated tirzepatide or semaglutide were included.
    Summary · context
    Propensity score matching (1:1) was applied to balance baseline characteristics, including age, sex, race, and cardiometabolic and psychiatric comorbidities.
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, tirzepatide versus semaglutide had a lower point estimate for Alzheimer's disease risk (RR 0.48), but the 95% CI of 0.22-1.01 ran up to no difference.

    In plain wordsIn adults with type 2 diabetes, Alzheimer's risk looked lower with tirzepatide than semaglutide, but the range was too wide to be sure.

    Peptide
    Tirzepatide
    Outcome
    No significant changeIncident Alzheimer's disease
    Study

    n = 44,470

    Comparator
    Semaglutide
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    RR
    0.48 ratio
    AD, tirzepatide vs semaglutide

    Source sentences

    Summary
    and AD (RR 0.48; 95% CI 0.22-1.01).
    2 context sentences
    Summary · context
    Adults with T2DM who initiated tirzepatide or semaglutide were included.
    Summary · context
    Propensity score matching (1:1) was applied to balance baseline characteristics, including age, sex, race, and cardiometabolic and psychiatric comorbidities.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.